ETJF personal page - To The Moon

ETJF

No personal profile

9Follow

1Followers

0Topic

0Badge

2021-06-13

Nice

Branson’s Virgin Orbit in talks with former Goldman partner’s SPAC for $3 billion deal to go public

2021-06-17

O

Vaccine sector stocks gained in pre-market trading.

2021-06-11

.

Can Alibaba Stock Hit $1,000? What's The Outlook

2022-04-18

Nice

Pfizer Draws Skeptics Amid Concerns Over Outlook for COVID-Related Sales

2021-06-13

Wow

Meme Stock Soars 1,000% To Lead These Two Top Small Cap Stock Plays

2021-02-04

Wow

Ant and Chinese Banks Are Reining In Joint Loans to Consumers

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3564047369816792","uuid":"3564047369816792","gmtCreate":1600954244237,"gmtModify":1600954244237,"name":"ETJF","pinyin":"etjf","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":9,"tweetSize":7,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.11.05","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.68%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.08%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":1,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":9081520206,"gmtCreate":1650254815805,"gmtModify":1676534680283,"author":{"id":"3564047369816792","authorId":"3564047369816792","name":"ETJF","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564047369816792","authorIdStr":"3564047369816792"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9081520206","repostId":"2228556987","repostType":4,"repost":{"id":"2228556987","pubTimestamp":1650252456,"share":"https://ttm.financial/m/news/2228556987?lang=&edition=fundamental","pubTime":"2022-04-18 11:27","market":"us","language":"en","title":"Pfizer Draws Skeptics Amid Concerns Over Outlook for COVID-Related Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2228556987","media":"seekingalpha","summary":"The earning season of large-cap pharma is set to kick off this week with the first quarter financial","content":"<html><head></head><body><p>The earning season of large-cap pharma is set to kick off this week with the first quarter financials of Johnson &amp; Johnson (JNJ). However, amid a recent selloff and a sharp decline in COVID-19 cases, its rival <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> has gained attention on Wall Street over the prospects for its COVID-related sales.</p><p>Despite a sharp recovery last month, <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> continues to trade 10% lower than its level at the start of the year, while J&amp;J (JNJ) and Merck (MRK), two of its pharma rivals with COVID-reliant businesses, have added ~5% and ~12%, respectively.</p><p>“For Pfizer, forecasting Comirnaty and Paxlovid remains a challenge,” Mizuho analysts led by Vamil Divan wrote this week, referring to the company’s COVID-19 vaccine and the antiviral by their brand names. With its 4Q 2021 results in February, the New York-based pharma giant projected $98B – $102B in revenue for this year, with more than half of the estimate attributed to the vaccine and pill sales at the midpoint of the forecast, based on contracts signed as of late-January.</p><p>Citing <a href=\"https://laohu8.com/S/IQV\">IQVIA</a> prescription trends, Mizuho expects the company to report 1Q 2022 revenue in line with the consensus. However, the analysts project lower than expected sales for Paxlovid, the breast cancer therapy, Ibrance and JAK inhibitor, Xeljanz.</p><p>Meanwhile, the sales of the COVID-19 vaccine could exceed Street forecasts driven by the demand outside the U.S., the team wrote, adding that sales of Pfizer&#39;s (PFE) heart failure therapy, Vyndamax, could also surpass expectations.</p><p>However, citing lower estimates for Comirnaty and Paxlovid, the firm has cut the 1Q revenue and EPS estimates for the company by ~12% and ~9% to $24.79B and $1.57, respectively.</p><p>Despite the success with the vaccine and pill, Mizuho reiterates the Neutral rating and $55 per share target on Pfizer (PFE) as the analysts point to the need for “more signs of pipeline success that will have a greater impact on Pfizer’s 2026-2030 outlook.”</p><p>The murky prospects for Pfizer’s (PFE) COVID-19 vaccine, its leading revenue generator last year, seem to have weighed on its valuation. Just last week, data analytics firm Airfinity cut the 2022 sales forecast for the vaccine by 15%.</p><p>However, after a two-month decline, the COVID-19 cases are on the rise in the U.S. again, fueled by highly transmissible Omicron BA. 2 subvariant. The data from Johns Hopkins University indicate that the daily new cases have climbed 14% since the start of April to approximately 32,000 cases per day, <i>The Financial Times</i> reported Saturday.</p><p>A potential uptick in COVID cases could make Pfizer&#39;s (PFE) valuation even more attractive, particularly after the recent selloff. On a non-GAAP basis, Pfizer’s (PFE) forward P/E stands at ~7.4x, with a ~42% discount to the five-year average, while those of rivals Merck (MRK) and J&amp;J (JNJ), which attributed ~10% and ~3% of 2022 revenue forecast to COVID-related sales, hover around ~12.0x and ~17.1x, respectively.</p><p>To become more constructive on Pfizer&#39;s (PFE) thesis, Divan and the Mizuho team seek further clarity on how the company will deploy the cashflows it generated from the vaccine and pill to improve its long-term outlook.</p><p>At a time the biotech valuations look compelling, the company appears to be on the deal hunt. Last month, it completed the acquisition of Arena Pharmaceuticals, a clinical-stage biotech focused on immuno-inflammatory diseases.</p><p>Announcing a proposed $525M deal to acquire privately-held ReViral, Pfizer (PFE) said early this month that the clinical-stage biopharma company could add over $1.5B in annual revenue if its programs become successful.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Draws Skeptics Amid Concerns Over Outlook for COVID-Related Sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Draws Skeptics Amid Concerns Over Outlook for COVID-Related Sales\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-18 11:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3823672-pfe-stock-in-focus-amid-concerns-over-outlook-for-covid-related-sales><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The earning season of large-cap pharma is set to kick off this week with the first quarter financials of Johnson & Johnson (JNJ). However, amid a recent selloff and a sharp decline in COVID-19 cases, ...</p>\n\n<a href=\"https://seekingalpha.com/news/3823672-pfe-stock-in-focus-amid-concerns-over-outlook-for-covid-related-sales\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://seekingalpha.com/news/3823672-pfe-stock-in-focus-amid-concerns-over-outlook-for-covid-related-sales","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2228556987","content_text":"The earning season of large-cap pharma is set to kick off this week with the first quarter financials of Johnson & Johnson (JNJ). However, amid a recent selloff and a sharp decline in COVID-19 cases, its rival Pfizer has gained attention on Wall Street over the prospects for its COVID-related sales.Despite a sharp recovery last month, Pfizer continues to trade 10% lower than its level at the start of the year, while J&J (JNJ) and Merck (MRK), two of its pharma rivals with COVID-reliant businesses, have added ~5% and ~12%, respectively.“For Pfizer, forecasting Comirnaty and Paxlovid remains a challenge,” Mizuho analysts led by Vamil Divan wrote this week, referring to the company’s COVID-19 vaccine and the antiviral by their brand names. With its 4Q 2021 results in February, the New York-based pharma giant projected $98B – $102B in revenue for this year, with more than half of the estimate attributed to the vaccine and pill sales at the midpoint of the forecast, based on contracts signed as of late-January.Citing IQVIA prescription trends, Mizuho expects the company to report 1Q 2022 revenue in line with the consensus. However, the analysts project lower than expected sales for Paxlovid, the breast cancer therapy, Ibrance and JAK inhibitor, Xeljanz.Meanwhile, the sales of the COVID-19 vaccine could exceed Street forecasts driven by the demand outside the U.S., the team wrote, adding that sales of Pfizer's (PFE) heart failure therapy, Vyndamax, could also surpass expectations.However, citing lower estimates for Comirnaty and Paxlovid, the firm has cut the 1Q revenue and EPS estimates for the company by ~12% and ~9% to $24.79B and $1.57, respectively.Despite the success with the vaccine and pill, Mizuho reiterates the Neutral rating and $55 per share target on Pfizer (PFE) as the analysts point to the need for “more signs of pipeline success that will have a greater impact on Pfizer’s 2026-2030 outlook.”The murky prospects for Pfizer’s (PFE) COVID-19 vaccine, its leading revenue generator last year, seem to have weighed on its valuation. Just last week, data analytics firm Airfinity cut the 2022 sales forecast for the vaccine by 15%.However, after a two-month decline, the COVID-19 cases are on the rise in the U.S. again, fueled by highly transmissible Omicron BA. 2 subvariant. The data from Johns Hopkins University indicate that the daily new cases have climbed 14% since the start of April to approximately 32,000 cases per day, The Financial Times reported Saturday.A potential uptick in COVID cases could make Pfizer's (PFE) valuation even more attractive, particularly after the recent selloff. On a non-GAAP basis, Pfizer’s (PFE) forward P/E stands at ~7.4x, with a ~42% discount to the five-year average, while those of rivals Merck (MRK) and J&J (JNJ), which attributed ~10% and ~3% of 2022 revenue forecast to COVID-related sales, hover around ~12.0x and ~17.1x, respectively.To become more constructive on Pfizer's (PFE) thesis, Divan and the Mizuho team seek further clarity on how the company will deploy the cashflows it generated from the vaccine and pill to improve its long-term outlook.At a time the biotech valuations look compelling, the company appears to be on the deal hunt. Last month, it completed the acquisition of Arena Pharmaceuticals, a clinical-stage biotech focused on immuno-inflammatory diseases.Announcing a proposed $525M deal to acquire privately-held ReViral, Pfizer (PFE) said early this month that the clinical-stage biopharma company could add over $1.5B in annual revenue if its programs become successful.","news_type":1},"isVote":1,"tweetType":1,"viewCount":110,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":161872662,"gmtCreate":1623920095056,"gmtModify":1703823519060,"author":{"id":"3564047369816792","authorId":"3564047369816792","name":"ETJF","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564047369816792","authorIdStr":"3564047369816792"},"themes":[],"htmlText":"O&nbsp;","listText":"O&nbsp;","text":"O","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/161872662","repostId":"1147243421","repostType":4,"repost":{"id":"1147243421","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1623918768,"share":"https://ttm.financial/m/news/1147243421?lang=&edition=fundamental","pubTime":"2021-06-17 16:32","market":"us","language":"en","title":"Vaccine sector stocks gained in pre-market trading.","url":"https://stock-news.laohu8.com/highlight/detail?id=1147243421","media":"Tiger Newspress","summary":"Vaccine sector stocks gained in pre-market trading.\nNovavax,Moderna and BioNTech shares were up bewt","content":"<p>Vaccine&nbsp;sector&nbsp;stocks gained in pre-market&nbsp;trading.</p>\n<p>Novavax,Moderna&nbsp;and&nbsp;BioNTech&nbsp;shares&nbsp;were&nbsp;up&nbsp;bewteen&nbsp;1%&nbsp;and&nbsp;5%.</p>\n<p><img src=\"https://static.tigerbbs.com/bcf7ccd098da30e231e2f93a2600de4a\" tg-width=\"1291\" tg-height=\"641\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccine sector stocks gained in pre-market trading.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccine sector stocks gained in pre-market trading.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-17 16:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Vaccine&nbsp;sector&nbsp;stocks gained in pre-market&nbsp;trading.</p>\n<p>Novavax,Moderna&nbsp;and&nbsp;BioNTech&nbsp;shares&nbsp;were&nbsp;up&nbsp;bewteen&nbsp;1%&nbsp;and&nbsp;5%.</p>\n<p><img src=\"https://static.tigerbbs.com/bcf7ccd098da30e231e2f93a2600de4a\" tg-width=\"1291\" tg-height=\"641\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1147243421","content_text":"Vaccine sector stocks gained in pre-market trading.\nNovavax,Moderna and BioNTech shares were up bewteen 1% and 5%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":820,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":182121550,"gmtCreate":1623558716970,"gmtModify":1704206161473,"author":{"id":"3564047369816792","authorId":"3564047369816792","name":"ETJF","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564047369816792","authorIdStr":"3564047369816792"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/182121550","repostId":"1185020128","repostType":4,"isVote":1,"tweetType":1,"viewCount":607,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":182120270,"gmtCreate":1623558585390,"gmtModify":1704206156579,"author":{"id":"3564047369816792","authorId":"3564047369816792","name":"ETJF","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564047369816792","authorIdStr":"3564047369816792"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/182120270","repostId":"1143408374","repostType":4,"repost":{"id":"1143408374","pubTimestamp":1623536483,"share":"https://ttm.financial/m/news/1143408374?lang=&edition=fundamental","pubTime":"2021-06-13 06:21","market":"us","language":"en","title":"Branson’s Virgin Orbit in talks with former Goldman partner’s SPAC for $3 billion deal to go public","url":"https://stock-news.laohu8.com/highlight/detail?id=1143408374","media":"cnbc","summary":"KEY POINTS\n\nVirgin Orbit, the satellite launching spinoff of Sir Richard Branson’s Virgin Galactic, ","content":"<div>\n<p>KEY POINTS\n\nVirgin Orbit, the satellite launching spinoff of Sir Richard Branson’s Virgin Galactic, is in advanced discussions to go public at about a $3 billion valuation through a SPAC, CNBC ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/12/virgin-orbit-in-talks-with-spac-for-3-billion-deal-to-go-public.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Branson’s Virgin Orbit in talks with former Goldman partner’s SPAC for $3 billion deal to go public</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBranson’s Virgin Orbit in talks with former Goldman partner’s SPAC for $3 billion deal to go public\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-13 06:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/12/virgin-orbit-in-talks-with-spac-for-3-billion-deal-to-go-public.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nVirgin Orbit, the satellite launching spinoff of Sir Richard Branson’s Virgin Galactic, is in advanced discussions to go public at about a $3 billion valuation through a SPAC, CNBC ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/12/virgin-orbit-in-talks-with-spac-for-3-billion-deal-to-go-public.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SPCE":"维珍银河"},"source_url":"https://www.cnbc.com/2021/06/12/virgin-orbit-in-talks-with-spac-for-3-billion-deal-to-go-public.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1143408374","content_text":"KEY POINTS\n\nVirgin Orbit, the satellite launching spinoff of Sir Richard Branson’s Virgin Galactic, is in advanced discussions to go public at about a $3 billion valuation through a SPAC, CNBC confirmed on Saturday.\nThe SPAC, led by a former Goldman Sachs partner, is NextGen Acquisition II, a person familiar with the discussions told CNBC.\nA deal expected to be announced in the coming weeks, the person said.\n\nVirgin Orbit, the satellite-launching spinoff ofSir Richard Branson’sVirgin Galactic, is in advanced discussions to go public at about a $3 billion valuation through a SPAC led by a formerGoldman Sachspartner, CNBC confirmed Saturday.\nThe company is in talks on a deal withNextGen Acquisition II, a person familiar with the discussions told CNBC. NextGen II is a special purpose acquisition company led by George Mattson, who previously co-led Goldman’s global industrials group.\nSky News first reportedthe talks on Saturday, saying a deal is expected to be announced in the coming weeks. Virgin Orbit declined CNBC’s request for comment.\nThe company is a spin-off of Branson’s space tourism company Virgin Galactic.Virgin Orbit isprivately heldby Branson’s multinational conglomerate Virgin Group, with a minority stake from Abu Dhabi sovereign wealth fund Mubadala.\nVirgin Orbit uses a modified Boeing 747 aircraft to launch its rockets, a method known as air launch. Rather than launch rockets from the ground, like competitors such as Rocket Lab or Astra, the company’s aircraft carries its LauncherOne rockets up to about 45,000 feet altitude and drops them just before they fire the engine and accelerate into space –a method the company touts as more flexiblethan a ground-based system.\nLauncherOne is designed to carry small satellites that weigh up to 500 kilograms, or about 1,100 pounds,into space. Virgin Orbit completed its first successful launch in January, and plans to conduct its second later this month.\nNext Gen II raised $375 million when it completed its initial public offering in October. The funds would largely go to help Virgin Orbit scale its business. Virgin Orbit CEO Dan Hart told CNBC in October that the company was seeking to raise about $150 million in fresh capital.\nBranson took Virgin Galactic publicthrough a SPAC deal in 2019withbillionaire investor Chamath Palihapitiya.","news_type":1},"isVote":1,"tweetType":1,"viewCount":711,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":183700317,"gmtCreate":1623346337239,"gmtModify":1704201456829,"author":{"id":"3564047369816792","authorId":"3564047369816792","name":"ETJF","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564047369816792","authorIdStr":"3564047369816792"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/183700317","repostId":"1107871315","repostType":4,"repost":{"id":"1107871315","pubTimestamp":1623315689,"share":"https://ttm.financial/m/news/1107871315?lang=&edition=fundamental","pubTime":"2021-06-10 17:01","market":"hk","language":"en","title":"Can Alibaba Stock Hit $1,000? What's The Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=1107871315","media":"seekingalpha","summary":"The \"promotional period\" for BABA shares has gone on for too long and patience is wearing thin. On the other hand, there's a camp of investors who welcome this.Alibaba has considerably more challenges on hand now than in early 2019 , yet the share price manages to be substantially higher.Drawing a straightforward trend line price chart, BABA shares could reach $1,000 sometime in the first quarter of 2027 if it crawls along with the support level.Alibaba's P/E ratio would compress to a mere 11 ti","content":"<p><b>Summary</b></p>\n<ul>\n <li>The \"promotional period\" for BABA shares has gone on for too long and patience is wearing thin. On the other hand, there's a camp of investors who welcome this.</li>\n <li>Alibaba has considerably more challenges on hand now than in early 2019 (U.S.-China trade war), yet the share price manages to be substantially higher.</li>\n <li>Drawing a straightforward trend line price chart, BABA shares could reach $1,000 sometime in the first quarter of 2027 if it crawls along with the support level.</li>\n <li>Alibaba's P/E ratio would compress to a mere 11 times on a forward basis (FY2026) and this is based on the current depressed environment.</li>\n <li>An investment in Alibaba has several risk factors and I wish to highlight two key ones.</li>\n</ul>\n<p><b>BABA stock is on sale</b></p>\n<p>Like the millions of items on its platforms, Alibaba Group (BABA) is on sale. Unfortunately, for many shareholders, the \"promotional period\" has gone on for too long and patience is wearing thin. On the other hand, there's a camp of investors who welcome this as it allows them to continue adding to their shares.</p>\n<p>Regardless, as a writer on numerousChinese internet stockswhose share prices have remained depressed for months and reading the harsh comments, it can get disheartening. As a shareholder in several of them myself, I understand the emotions going through the mind.</p>\n<p>At the same time, there have been many wise readers and fellow authors who provided sound advice that keeps me on the path. For instance, Gary Alexander recently wrote regarding thetech sell-off:</p>\n<blockquote>\n \"When the selloff in the tech sector has proven to be this indiscriminate (good and bad, cheap and expensive stocks are all being sold off at roughly the same pace), it's our job as diligent investors to be extremely discerning in the buying opportunities that have surfaced.\"\n</blockquote>\n<p>With BABA stock having given up all its gains in the past year, it's scant comfort to know the share price is still 58 percent higher than early 2019. Nevertheless, I am bringing this up because Alibaba was being shunned by investors then due to the headwinds from the U.S.-China trade war.</p>\n<p><img src=\"https://static.tigerbbs.com/e90c1a30b5b83eb51c67338eab37cb5e\" tg-width=\"640\" tg-height=\"451\" referrerpolicy=\"no-referrer\"></p>\n<p>Now that the e-commerce and cloud giant has considerably more challenges on hand, yet the share price manages to be substantially higher. This provides a glimpse into the possible future where Alibaba Group Holding Limited overcome its immediate struggles and investors clamor for its shares again.</p>\n<p>That said, how do we justify that BABA stock is on sale? Well, let's look at the valuation. Both Alibaba Group and its U.S. peer Amazon.com (AMZN) have delivered solid revenue and earnings growth in the past years. The improvement in business fundamentals has led investors in both companies to think it would only get tougher to achieve returns expected of a growth stock, compressing their price-earnings multiples.</p>\n<p>Looking at the more representative enterprise value to free cash flow [EV/FCF] ratio, it becomes apparent that the market is valuing Alibaba much lower than Amazon. The EV/FCF is only 16 times for Alibaba and 72 times for Amazon.</p>\n<p><img src=\"https://static.tigerbbs.com/57bda237a374d7f6688c298b0fe9ae21\" tg-width=\"640\" tg-height=\"493\" referrerpolicy=\"no-referrer\"></p>\n<p>With a 3-year revenue CAGR and a 5-year revenue CAGR above 40 percent, it's hard to argue Alibaba Group is not a growth stock. Amazon only managed to deliver around 30 percent CAGR for both its 3-year and 5-year revenues. For the last reported quarter, Alibaba scored a 64 percent increase in revenue. Its forward revenue growth of 35.3 percent surpasses that of Amazon as well.</p>\n<table>\n <tbody>\n  <tr>\n   <td>BABA</td>\n   <td>AMZN</td>\n  </tr>\n  <tr>\n   <td>Revenue Growth [YoY]</td>\n   <td><p>40.7%</p></td>\n   <td><p>41.5%</p></td>\n  </tr>\n  <tr>\n   <td>Revenue Growth [FWD]</td>\n   <td><p>35.3%</p></td>\n   <td><p>27.2%</p></td>\n  </tr>\n  <tr>\n   <td>Revenue 3 Year [CAGR]</td>\n   <td><p>42.1%</p></td>\n   <td><p>29.5%</p></td>\n  </tr>\n  <tr>\n   <td>Revenue 5 Year [CAGR]</td>\n   <td><p>48.0%</p></td>\n   <td><p>29.9%</p></td>\n  </tr>\n </tbody>\n</table>\n<p><i>Source: Seeking Alpha Premium (data extracted on June 6, 2021)</i></p>\n<p>During times of uncertainty, it is imperative that companies have plenty of liquidity. Alibaba has loads of cash. Its EV to net cash is at a low 11.5 times compared to 36.6 times for Amazon. In other words, Alibaba has much more cash at its disposal relative to Amazon when we compare the enterprise values of the two companies. With the financial heft to withstand regulatory changes and geopolitical headwinds, it seems BABA shares are now at a bargain.</p>\n<p><b>Alibaba stock forecast</b></p>\n<p>The circumstances leading to the rough patch that Alibaba Group has found itself in are well-publicized. For the uninitiated, here are the key hurdles the company has faced:</p>\n<ul>\n <li>Theeleventh-hour suspensionof the IPO of Ant Group, its fintech arm;</li>\n <li>The\"disappearance\" of Jack Ma, the flamboyant founder of Alibaba Group;</li>\n <li>Antimonopoly investigation on its e-commerce practices and the subsequentpenalty meted out;</li>\n <li>Restructuring of Ant Group such that its finance lending unit isregulated like a bank, crimping its valuation.</li>\n</ul>\n<p>Considering the earlier mentioned formidable headwinds, it might seem ludicrous to think BABA stock can hit $1000 per share, more than quadruple the current price. Nevertheless, drawing a straightforward trend line price chart, BABA shares could reach $1000 sometime in the first quarter of 2027, if it crawls along with the support level.</p>\n<p><img src=\"https://static.tigerbbs.com/00dc7dd1ce5e1c05708abe460be89359\" tg-width=\"640\" tg-height=\"249\" referrerpolicy=\"no-referrer\"></p>\n<p><i>Source: Yahoo Finance (chart drawn by ALT Perspective)</i></p>\n<p>Do note that I am not factoring in any share consolidation in the interim. I am also not considering the scenario that Alibaba becomes a meme stock which is possible since Redditors tend to promote stocks that are \"hated\" by the market. I am assuming the adage that the stock market is a weighing machine, in the long run, will come to fruition for BABA.</p>\n<p>Is that thought farfetched? Just a couple of months back, I would answer a categorical no. However, as you will see from the chart, BABA's share price has dipped below the long-term support line. Some stocks have experienced such a chart pattern and managed to return above the support-turned-resistance line. It would not be easy but it has happened.</p>\n<p>Of course, the question here is whether $1000 per share is something foreseeable in the future. I say yes, provided the stock can regain its composure and get back up to the multi-year trend line in the next few months or so. If the stock drifts further south instead, the recovery back to the long-term support line would be too onerous, not to mention to get back on the track to $1000.</p>\n<p>The consensus one-year price target for BABA is at $295.60, 37 percent above the prevailing price. Even if the price target does not get revised upwards through the rest of the year, hitting near that level would bring the share price well above the $278 where the support line will be at the end of 2021. This means it isn't that difficult for Alibaba to return to its uptrend.</p>\n<p><img src=\"https://static.tigerbbs.com/6a8487c8f5276e6dd30d79d024833563\" tg-width=\"640\" tg-height=\"478\" referrerpolicy=\"no-referrer\"></p>\n<p><b>Is Alibaba a good long-term stock?</b></p>\n<p>It is common nowadays to read media headlines and comments about fund managers \"dumping BABA stock\". Thus, it came as a surprise to me that Alibaba Group Holding was ranked fifth among \"50 stocks that matter the most to hedge funds,\" according to the Goldman Sachs'Hedge Fund VIP List.</p>\n<p>As many as 77 funds with 10 to 200 positions have Alibaba Group in their portfolios as of 31 March 2021, way higher than the median of 44 for the other stocks. Alibaba even found itself in the top 10 holdings in 35 funds. The average portfolio weight of BABA stock in these funds was 6 percent, the same weighting as Amazon and Visa Inc. (V). The percentage of equity cap of Alibaba owned by hedge funds was 2 percent, also the same as Amazon.</p>\n<p>Masayoshi Son, the CEO of SoftBank Group (OTCPK:SFTBY) (OTCPK:SFTBF), recently commented that Alibaba is \"a great company, at a low price compared with its fundamentals.\" As SoftBank is a substantial shareholder of Alibaba, perhaps some readers are not convinced.</p>\n<p>However, Alibaba is becoming such a value stock that even \"Warren Buffett would love,\" according to a recent<i>Barron's</i>article. In a selection of high-scoring U.S. stocks from the Validea Buffett model, with market values above $10 billion, Alibaba Group was among the 10 finalists. Of particular note, it received a perfect score based on the Buffett model.</p>\n<p>What are we missing here? According to the consensus forecast, Alibaba is projected to double its earnings per share to nearly $20 in fiscal year ending March 2026, up from the $10.10 it reported in the fiscal year ending March 2021. Correspondingly, its P/E ratio would compress to a mere 11 times on a forward basis, if the share price stayed stagnant.</p>\n<p><img src=\"https://static.tigerbbs.com/3e98d8e98b1ce9bd2ec6a1275eb329f9\" tg-width=\"640\" tg-height=\"276\" referrerpolicy=\"no-referrer\"></p>\n<p><i>Source: Seeking Alpha Premium</i></p>\n<p>If the share price does reach $1000, the P/E ratio would be more than 40 times. That would mean a rather rich valuation for Alibaba. However, we have to consider that the formidable headwinds facing the company have resulted in analysts churning out conservative numbers and price targets. As we can see from the following table, the EPS forecast is premised on the revenue growth steadily declining from the 5-year revenue CAGR of 48 percent to the low teens by 2026.</p>\n<p><img src=\"https://static.tigerbbs.com/7b2476ae016bd40d9b86476464121313\" tg-width=\"640\" tg-height=\"207\" referrerpolicy=\"no-referrer\"></p>\n<p><i>Source: Seeking Alpha Premium</i></p>\n<p>When Alibaba Group continues to deliver steady revenue and earnings growth over the coming years, coupled with a potentialsustained change in narrative, the sentiment towards the stock could switch back to positive and we could once again see analysts revising their projections in reaction.</p>\n<p><b>Risk factors for Alibaba investors</b></p>\n<p>An investment in Alibaba has several risk factors and I wish to highlight two key ones. First, its ADR shares are listed through a Variable Interest Entity [VIE] structure. Some analysts haveraised the concernthat the Chinese government could one day declare the VIE void and the shares could become worthless overnight technically.</p>\n<p>Rationally though, it does not make sense for Beijing to disavow the VIE structure. Listing on the U.S. markets enables its companies to secure funding for business growth which would, in turn, boost the Chinese economy as well as create jobs.</p>\n<p>Second, the Holding Foreign Companies Accountable Act [HFCAA]signed into lawon 18 December 2020 could result in BABA ADRs delisted from U.S. stock exchanges if Alibaba is unable to fulfill the conditions as stipulated in the Act. The company CFO, Maggie Wu, has expressed her confidence that Alibaba cancomply withthe requirements of the HFCAA.</p>\n<p>Nevertheless, the U.S. government can issue amendments to the Act as it hasdone soin March. There is no certainty that Alibaba would be able to meet all future changes to the HFCAA. Investors have to take such risks into consideration.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Can Alibaba Stock Hit $1,000? What's The Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCan Alibaba Stock Hit $1,000? What's The Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-10 17:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4433917-can-alibaba-stock-hit-1000><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nThe \"promotional period\" for BABA shares has gone on for too long and patience is wearing thin. On the other hand, there's a camp of investors who welcome this.\nAlibaba has considerably more ...</p>\n\n<a href=\"https://seekingalpha.com/article/4433917-can-alibaba-stock-hit-1000\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BABA":"阿里巴巴","09988":"阿里巴巴-W"},"source_url":"https://seekingalpha.com/article/4433917-can-alibaba-stock-hit-1000","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1107871315","content_text":"Summary\n\nThe \"promotional period\" for BABA shares has gone on for too long and patience is wearing thin. On the other hand, there's a camp of investors who welcome this.\nAlibaba has considerably more challenges on hand now than in early 2019 (U.S.-China trade war), yet the share price manages to be substantially higher.\nDrawing a straightforward trend line price chart, BABA shares could reach $1,000 sometime in the first quarter of 2027 if it crawls along with the support level.\nAlibaba's P/E ratio would compress to a mere 11 times on a forward basis (FY2026) and this is based on the current depressed environment.\nAn investment in Alibaba has several risk factors and I wish to highlight two key ones.\n\nBABA stock is on sale\nLike the millions of items on its platforms, Alibaba Group (BABA) is on sale. Unfortunately, for many shareholders, the \"promotional period\" has gone on for too long and patience is wearing thin. On the other hand, there's a camp of investors who welcome this as it allows them to continue adding to their shares.\nRegardless, as a writer on numerousChinese internet stockswhose share prices have remained depressed for months and reading the harsh comments, it can get disheartening. As a shareholder in several of them myself, I understand the emotions going through the mind.\nAt the same time, there have been many wise readers and fellow authors who provided sound advice that keeps me on the path. For instance, Gary Alexander recently wrote regarding thetech sell-off:\n\n \"When the selloff in the tech sector has proven to be this indiscriminate (good and bad, cheap and expensive stocks are all being sold off at roughly the same pace), it's our job as diligent investors to be extremely discerning in the buying opportunities that have surfaced.\"\n\nWith BABA stock having given up all its gains in the past year, it's scant comfort to know the share price is still 58 percent higher than early 2019. Nevertheless, I am bringing this up because Alibaba was being shunned by investors then due to the headwinds from the U.S.-China trade war.\n\nNow that the e-commerce and cloud giant has considerably more challenges on hand, yet the share price manages to be substantially higher. This provides a glimpse into the possible future where Alibaba Group Holding Limited overcome its immediate struggles and investors clamor for its shares again.\nThat said, how do we justify that BABA stock is on sale? Well, let's look at the valuation. Both Alibaba Group and its U.S. peer Amazon.com (AMZN) have delivered solid revenue and earnings growth in the past years. The improvement in business fundamentals has led investors in both companies to think it would only get tougher to achieve returns expected of a growth stock, compressing their price-earnings multiples.\nLooking at the more representative enterprise value to free cash flow [EV/FCF] ratio, it becomes apparent that the market is valuing Alibaba much lower than Amazon. The EV/FCF is only 16 times for Alibaba and 72 times for Amazon.\n\nWith a 3-year revenue CAGR and a 5-year revenue CAGR above 40 percent, it's hard to argue Alibaba Group is not a growth stock. Amazon only managed to deliver around 30 percent CAGR for both its 3-year and 5-year revenues. For the last reported quarter, Alibaba scored a 64 percent increase in revenue. Its forward revenue growth of 35.3 percent surpasses that of Amazon as well.\n\n\n\nBABA\nAMZN\n\n\nRevenue Growth [YoY]\n40.7%\n41.5%\n\n\nRevenue Growth [FWD]\n35.3%\n27.2%\n\n\nRevenue 3 Year [CAGR]\n42.1%\n29.5%\n\n\nRevenue 5 Year [CAGR]\n48.0%\n29.9%\n\n\n\nSource: Seeking Alpha Premium (data extracted on June 6, 2021)\nDuring times of uncertainty, it is imperative that companies have plenty of liquidity. Alibaba has loads of cash. Its EV to net cash is at a low 11.5 times compared to 36.6 times for Amazon. In other words, Alibaba has much more cash at its disposal relative to Amazon when we compare the enterprise values of the two companies. With the financial heft to withstand regulatory changes and geopolitical headwinds, it seems BABA shares are now at a bargain.\nAlibaba stock forecast\nThe circumstances leading to the rough patch that Alibaba Group has found itself in are well-publicized. For the uninitiated, here are the key hurdles the company has faced:\n\nTheeleventh-hour suspensionof the IPO of Ant Group, its fintech arm;\nThe\"disappearance\" of Jack Ma, the flamboyant founder of Alibaba Group;\nAntimonopoly investigation on its e-commerce practices and the subsequentpenalty meted out;\nRestructuring of Ant Group such that its finance lending unit isregulated like a bank, crimping its valuation.\n\nConsidering the earlier mentioned formidable headwinds, it might seem ludicrous to think BABA stock can hit $1000 per share, more than quadruple the current price. Nevertheless, drawing a straightforward trend line price chart, BABA shares could reach $1000 sometime in the first quarter of 2027, if it crawls along with the support level.\n\nSource: Yahoo Finance (chart drawn by ALT Perspective)\nDo note that I am not factoring in any share consolidation in the interim. I am also not considering the scenario that Alibaba becomes a meme stock which is possible since Redditors tend to promote stocks that are \"hated\" by the market. I am assuming the adage that the stock market is a weighing machine, in the long run, will come to fruition for BABA.\nIs that thought farfetched? Just a couple of months back, I would answer a categorical no. However, as you will see from the chart, BABA's share price has dipped below the long-term support line. Some stocks have experienced such a chart pattern and managed to return above the support-turned-resistance line. It would not be easy but it has happened.\nOf course, the question here is whether $1000 per share is something foreseeable in the future. I say yes, provided the stock can regain its composure and get back up to the multi-year trend line in the next few months or so. If the stock drifts further south instead, the recovery back to the long-term support line would be too onerous, not to mention to get back on the track to $1000.\nThe consensus one-year price target for BABA is at $295.60, 37 percent above the prevailing price. Even if the price target does not get revised upwards through the rest of the year, hitting near that level would bring the share price well above the $278 where the support line will be at the end of 2021. This means it isn't that difficult for Alibaba to return to its uptrend.\n\nIs Alibaba a good long-term stock?\nIt is common nowadays to read media headlines and comments about fund managers \"dumping BABA stock\". Thus, it came as a surprise to me that Alibaba Group Holding was ranked fifth among \"50 stocks that matter the most to hedge funds,\" according to the Goldman Sachs'Hedge Fund VIP List.\nAs many as 77 funds with 10 to 200 positions have Alibaba Group in their portfolios as of 31 March 2021, way higher than the median of 44 for the other stocks. Alibaba even found itself in the top 10 holdings in 35 funds. The average portfolio weight of BABA stock in these funds was 6 percent, the same weighting as Amazon and Visa Inc. (V). The percentage of equity cap of Alibaba owned by hedge funds was 2 percent, also the same as Amazon.\nMasayoshi Son, the CEO of SoftBank Group (OTCPK:SFTBY) (OTCPK:SFTBF), recently commented that Alibaba is \"a great company, at a low price compared with its fundamentals.\" As SoftBank is a substantial shareholder of Alibaba, perhaps some readers are not convinced.\nHowever, Alibaba is becoming such a value stock that even \"Warren Buffett would love,\" according to a recentBarron'sarticle. In a selection of high-scoring U.S. stocks from the Validea Buffett model, with market values above $10 billion, Alibaba Group was among the 10 finalists. Of particular note, it received a perfect score based on the Buffett model.\nWhat are we missing here? According to the consensus forecast, Alibaba is projected to double its earnings per share to nearly $20 in fiscal year ending March 2026, up from the $10.10 it reported in the fiscal year ending March 2021. Correspondingly, its P/E ratio would compress to a mere 11 times on a forward basis, if the share price stayed stagnant.\n\nSource: Seeking Alpha Premium\nIf the share price does reach $1000, the P/E ratio would be more than 40 times. That would mean a rather rich valuation for Alibaba. However, we have to consider that the formidable headwinds facing the company have resulted in analysts churning out conservative numbers and price targets. As we can see from the following table, the EPS forecast is premised on the revenue growth steadily declining from the 5-year revenue CAGR of 48 percent to the low teens by 2026.\n\nSource: Seeking Alpha Premium\nWhen Alibaba Group continues to deliver steady revenue and earnings growth over the coming years, coupled with a potentialsustained change in narrative, the sentiment towards the stock could switch back to positive and we could once again see analysts revising their projections in reaction.\nRisk factors for Alibaba investors\nAn investment in Alibaba has several risk factors and I wish to highlight two key ones. First, its ADR shares are listed through a Variable Interest Entity [VIE] structure. Some analysts haveraised the concernthat the Chinese government could one day declare the VIE void and the shares could become worthless overnight technically.\nRationally though, it does not make sense for Beijing to disavow the VIE structure. Listing on the U.S. markets enables its companies to secure funding for business growth which would, in turn, boost the Chinese economy as well as create jobs.\nSecond, the Holding Foreign Companies Accountable Act [HFCAA]signed into lawon 18 December 2020 could result in BABA ADRs delisted from U.S. stock exchanges if Alibaba is unable to fulfill the conditions as stipulated in the Act. The company CFO, Maggie Wu, has expressed her confidence that Alibaba cancomply withthe requirements of the HFCAA.\nNevertheless, the U.S. government can issue amendments to the Act as it hasdone soin March. There is no certainty that Alibaba would be able to meet all future changes to the HFCAA. Investors have to take such risks into consideration.","news_type":1},"isVote":1,"tweetType":1,"viewCount":624,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":317333114,"gmtCreate":1612415311838,"gmtModify":1704870845655,"author":{"id":"3564047369816792","authorId":"3564047369816792","name":"ETJF","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564047369816792","authorIdStr":"3564047369816792"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/317333114","repostId":"2108791116","repostType":4,"repost":{"id":"2108791116","pubTimestamp":1612407835,"share":"https://ttm.financial/m/news/2108791116?lang=&edition=fundamental","pubTime":"2021-02-04 11:03","market":"us","language":"en","title":"Ant and Chinese Banks Are Reining In Joint Loans to Consumers","url":"https://stock-news.laohu8.com/highlight/detail?id=2108791116","media":"Bloomberg","summary":"(Bloomberg) -- Ant Group Co. and at least a dozen banks are paring back their years-long cooperation","content":"<p>(Bloomberg) -- Ant Group Co. and at least a dozen banks are paring back their years-long cooperation on consumer lending platforms that fuel the spending of at least 500 million people across China.</p>\n<p>Regulators have signaled their intention to curb online loans in recent months, prompting banks and Ant itself to discuss lending caps, people familiar with the matter said, asking not to be identified discussing a private information.</p>\n<p>Banks in Zhejiang province have been instructed to cut their exposure to Ant via joint loans on the firm’s Jiebei and Huabei platforms, the people said. Some lenders in Shanghai have set a timetable for a gradual reduction in joint offerings, while at least <a href=\"https://laohu8.com/S/AONE\">one</a> in Shandong has completely suspended ties with the firm, the people said.</p>\n<p>The moves have taken place in parallel with Ant’s discussions with Chinese authorities on a restructuring plan. Bloomberg reported on Wednesday that Ant has agreed to become a financial holding company, making it subject to capital requirements similar to those for banks.</p>\n<p>Consumer credit has been crucial in driving growth at Ant’s digital finance business, which contributed 63% of the firm’s revenue in the first half of 2020 before the authorities unleashed a barrage of rules to curb the country’s booming financial technology industry. Regulators also want to prevent any <a href=\"https://laohu8.com/S/AONE.U\">one</a> firm from becoming too dominant.</p>\n<p>The regulators upended a $35 billion initial public offering by Ant Group in November, stunning investors from Shanghai to New York. In a conference call with investors on Tuesday, Alibaba Group Holding Ltd. Chief Executive Officer Daniel Zhang said there is “substantial uncertainty” with Ant’s business and it is difficult to assess the impact of the new regulations. Alibaba owns a third of Ant and both were founded by billionaire Jack Ma.</p>\n<p>Ant declined to comment. The China Banking and Insurance Regulatory Commission didn’t immediately respond to a request seeking comment.</p>\n<p>Among the hardest-hitting for Ant was the proposal to impose additional capital requirements on microlenders and demand that fintech platforms put up at least 30% of the funding for loans that are jointly offered with banks. Before the proposal, only about 2% of the more than 1.7 trillion yuan ($263 billion) in loans remained on Ant’s balance sheet, with the bulk of funding coming from its about 100 bank partners.</p>\n<p>Ant needs to inject at least 70 billion yuan of new capital just for its credit-lending business to comply with the regulation, according to a November estimate by Francis Chan, a senior analyst at Bloomberg Intelligence in Hong Kong.</p>\n<p>Liang Tao, vice chairman of the China Banking and Insurance Regulatory Commission, said last month recent measures weren’t aimed at any specific company and have been well received by some in the industry. Some of the firms have a “relatively positive attitude” toward the new requirements and have achieved “initial effects” in their “rectification” efforts, he said.</p>\n<p>Banks and insurers should continue to cooperate normally with internet platforms in compliance with laws and regulations and some lenders that have pulled back should correct their behavior, Liang said, without elaborating.</p>\n<p>Still, local banking regulators in provinces including Zhejiang and Hunan are urging banks that have relied heavily on Ant for client referrals and lending growth to cut back, said the people.</p>\n<p>“While the restructuring would bring Ant a step closer to relaunching its IPO, all its units face more restrictions on capital, leverage and product pricing, risking growth,” said Chan, who estimated Ant’s valuation may have fallen to below $108 billion from a $280 billion pre-money valuation ahead of its failed IPO.</p>\n<p></p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ant and Chinese Banks Are Reining In Joint Loans to Consumers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnt and Chinese Banks Are Reining In Joint Loans to Consumers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-02-04 11:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/ant-chinese-banks-reining-joint-010651856.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Ant Group Co. and at least a dozen banks are paring back their years-long cooperation on consumer lending platforms that fuel the spending of at least 500 million people across China.\n...</p>\n\n<a href=\"https://finance.yahoo.com/news/ant-chinese-banks-reining-joint-010651856.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/1684aaaa06891b8d2dd04a9941acb502","relate_stocks":{"BABA":"阿里巴巴","09988":"阿里巴巴-W"},"source_url":"https://finance.yahoo.com/news/ant-chinese-banks-reining-joint-010651856.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2108791116","content_text":"(Bloomberg) -- Ant Group Co. and at least a dozen banks are paring back their years-long cooperation on consumer lending platforms that fuel the spending of at least 500 million people across China.\nRegulators have signaled their intention to curb online loans in recent months, prompting banks and Ant itself to discuss lending caps, people familiar with the matter said, asking not to be identified discussing a private information.\nBanks in Zhejiang province have been instructed to cut their exposure to Ant via joint loans on the firm’s Jiebei and Huabei platforms, the people said. Some lenders in Shanghai have set a timetable for a gradual reduction in joint offerings, while at least one in Shandong has completely suspended ties with the firm, the people said.\nThe moves have taken place in parallel with Ant’s discussions with Chinese authorities on a restructuring plan. Bloomberg reported on Wednesday that Ant has agreed to become a financial holding company, making it subject to capital requirements similar to those for banks.\nConsumer credit has been crucial in driving growth at Ant’s digital finance business, which contributed 63% of the firm’s revenue in the first half of 2020 before the authorities unleashed a barrage of rules to curb the country’s booming financial technology industry. Regulators also want to prevent any one firm from becoming too dominant.\nThe regulators upended a $35 billion initial public offering by Ant Group in November, stunning investors from Shanghai to New York. In a conference call with investors on Tuesday, Alibaba Group Holding Ltd. Chief Executive Officer Daniel Zhang said there is “substantial uncertainty” with Ant’s business and it is difficult to assess the impact of the new regulations. Alibaba owns a third of Ant and both were founded by billionaire Jack Ma.\nAnt declined to comment. The China Banking and Insurance Regulatory Commission didn’t immediately respond to a request seeking comment.\nAmong the hardest-hitting for Ant was the proposal to impose additional capital requirements on microlenders and demand that fintech platforms put up at least 30% of the funding for loans that are jointly offered with banks. Before the proposal, only about 2% of the more than 1.7 trillion yuan ($263 billion) in loans remained on Ant’s balance sheet, with the bulk of funding coming from its about 100 bank partners.\nAnt needs to inject at least 70 billion yuan of new capital just for its credit-lending business to comply with the regulation, according to a November estimate by Francis Chan, a senior analyst at Bloomberg Intelligence in Hong Kong.\nLiang Tao, vice chairman of the China Banking and Insurance Regulatory Commission, said last month recent measures weren’t aimed at any specific company and have been well received by some in the industry. Some of the firms have a “relatively positive attitude” toward the new requirements and have achieved “initial effects” in their “rectification” efforts, he said.\nBanks and insurers should continue to cooperate normally with internet platforms in compliance with laws and regulations and some lenders that have pulled back should correct their behavior, Liang said, without elaborating.\nStill, local banking regulators in provinces including Zhejiang and Hunan are urging banks that have relied heavily on Ant for client referrals and lending growth to cut back, said the people.\n“While the restructuring would bring Ant a step closer to relaunching its IPO, all its units face more restrictions on capital, leverage and product pricing, risking growth,” said Chan, who estimated Ant’s valuation may have fallen to below $108 billion from a $280 billion pre-money valuation ahead of its failed IPO.","news_type":1},"isVote":1,"tweetType":1,"viewCount":520,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":182120270,"gmtCreate":1623558585390,"gmtModify":1704206156579,"author":{"id":"3564047369816792","authorId":"3564047369816792","name":"ETJF","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564047369816792","authorIdStr":"3564047369816792"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/182120270","repostId":"1143408374","repostType":4,"repost":{"id":"1143408374","pubTimestamp":1623536483,"share":"https://ttm.financial/m/news/1143408374?lang=&edition=fundamental","pubTime":"2021-06-13 06:21","market":"us","language":"en","title":"Branson’s Virgin Orbit in talks with former Goldman partner’s SPAC for $3 billion deal to go public","url":"https://stock-news.laohu8.com/highlight/detail?id=1143408374","media":"cnbc","summary":"KEY POINTS\n\nVirgin Orbit, the satellite launching spinoff of Sir Richard Branson’s Virgin Galactic, ","content":"<div>\n<p>KEY POINTS\n\nVirgin Orbit, the satellite launching spinoff of Sir Richard Branson’s Virgin Galactic, is in advanced discussions to go public at about a $3 billion valuation through a SPAC, CNBC ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/12/virgin-orbit-in-talks-with-spac-for-3-billion-deal-to-go-public.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Branson’s Virgin Orbit in talks with former Goldman partner’s SPAC for $3 billion deal to go public</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBranson’s Virgin Orbit in talks with former Goldman partner’s SPAC for $3 billion deal to go public\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-13 06:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/12/virgin-orbit-in-talks-with-spac-for-3-billion-deal-to-go-public.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nVirgin Orbit, the satellite launching spinoff of Sir Richard Branson’s Virgin Galactic, is in advanced discussions to go public at about a $3 billion valuation through a SPAC, CNBC ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/12/virgin-orbit-in-talks-with-spac-for-3-billion-deal-to-go-public.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SPCE":"维珍银河"},"source_url":"https://www.cnbc.com/2021/06/12/virgin-orbit-in-talks-with-spac-for-3-billion-deal-to-go-public.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1143408374","content_text":"KEY POINTS\n\nVirgin Orbit, the satellite launching spinoff of Sir Richard Branson’s Virgin Galactic, is in advanced discussions to go public at about a $3 billion valuation through a SPAC, CNBC confirmed on Saturday.\nThe SPAC, led by a former Goldman Sachs partner, is NextGen Acquisition II, a person familiar with the discussions told CNBC.\nA deal expected to be announced in the coming weeks, the person said.\n\nVirgin Orbit, the satellite-launching spinoff ofSir Richard Branson’sVirgin Galactic, is in advanced discussions to go public at about a $3 billion valuation through a SPAC led by a formerGoldman Sachspartner, CNBC confirmed Saturday.\nThe company is in talks on a deal withNextGen Acquisition II, a person familiar with the discussions told CNBC. NextGen II is a special purpose acquisition company led by George Mattson, who previously co-led Goldman’s global industrials group.\nSky News first reportedthe talks on Saturday, saying a deal is expected to be announced in the coming weeks. Virgin Orbit declined CNBC’s request for comment.\nThe company is a spin-off of Branson’s space tourism company Virgin Galactic.Virgin Orbit isprivately heldby Branson’s multinational conglomerate Virgin Group, with a minority stake from Abu Dhabi sovereign wealth fund Mubadala.\nVirgin Orbit uses a modified Boeing 747 aircraft to launch its rockets, a method known as air launch. Rather than launch rockets from the ground, like competitors such as Rocket Lab or Astra, the company’s aircraft carries its LauncherOne rockets up to about 45,000 feet altitude and drops them just before they fire the engine and accelerate into space –a method the company touts as more flexiblethan a ground-based system.\nLauncherOne is designed to carry small satellites that weigh up to 500 kilograms, or about 1,100 pounds,into space. Virgin Orbit completed its first successful launch in January, and plans to conduct its second later this month.\nNext Gen II raised $375 million when it completed its initial public offering in October. The funds would largely go to help Virgin Orbit scale its business. Virgin Orbit CEO Dan Hart told CNBC in October that the company was seeking to raise about $150 million in fresh capital.\nBranson took Virgin Galactic publicthrough a SPAC deal in 2019withbillionaire investor Chamath Palihapitiya.","news_type":1},"isVote":1,"tweetType":1,"viewCount":711,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":161872662,"gmtCreate":1623920095056,"gmtModify":1703823519060,"author":{"id":"3564047369816792","authorId":"3564047369816792","name":"ETJF","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564047369816792","authorIdStr":"3564047369816792"},"themes":[],"htmlText":"O&nbsp;","listText":"O&nbsp;","text":"O","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/161872662","repostId":"1147243421","repostType":4,"repost":{"id":"1147243421","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1623918768,"share":"https://ttm.financial/m/news/1147243421?lang=&edition=fundamental","pubTime":"2021-06-17 16:32","market":"us","language":"en","title":"Vaccine sector stocks gained in pre-market trading.","url":"https://stock-news.laohu8.com/highlight/detail?id=1147243421","media":"Tiger Newspress","summary":"Vaccine sector stocks gained in pre-market trading.\nNovavax,Moderna and BioNTech shares were up bewt","content":"<p>Vaccine&nbsp;sector&nbsp;stocks gained in pre-market&nbsp;trading.</p>\n<p>Novavax,Moderna&nbsp;and&nbsp;BioNTech&nbsp;shares&nbsp;were&nbsp;up&nbsp;bewteen&nbsp;1%&nbsp;and&nbsp;5%.</p>\n<p><img src=\"https://static.tigerbbs.com/bcf7ccd098da30e231e2f93a2600de4a\" tg-width=\"1291\" tg-height=\"641\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccine sector stocks gained in pre-market trading.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccine sector stocks gained in pre-market trading.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-17 16:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Vaccine&nbsp;sector&nbsp;stocks gained in pre-market&nbsp;trading.</p>\n<p>Novavax,Moderna&nbsp;and&nbsp;BioNTech&nbsp;shares&nbsp;were&nbsp;up&nbsp;bewteen&nbsp;1%&nbsp;and&nbsp;5%.</p>\n<p><img src=\"https://static.tigerbbs.com/bcf7ccd098da30e231e2f93a2600de4a\" tg-width=\"1291\" tg-height=\"641\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1147243421","content_text":"Vaccine sector stocks gained in pre-market trading.\nNovavax,Moderna and BioNTech shares were up bewteen 1% and 5%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":820,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":183700317,"gmtCreate":1623346337239,"gmtModify":1704201456829,"author":{"id":"3564047369816792","authorId":"3564047369816792","name":"ETJF","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564047369816792","authorIdStr":"3564047369816792"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/183700317","repostId":"1107871315","repostType":4,"repost":{"id":"1107871315","pubTimestamp":1623315689,"share":"https://ttm.financial/m/news/1107871315?lang=&edition=fundamental","pubTime":"2021-06-10 17:01","market":"hk","language":"en","title":"Can Alibaba Stock Hit $1,000? What's The Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=1107871315","media":"seekingalpha","summary":"The \"promotional period\" for BABA shares has gone on for too long and patience is wearing thin. On the other hand, there's a camp of investors who welcome this.Alibaba has considerably more challenges on hand now than in early 2019 , yet the share price manages to be substantially higher.Drawing a straightforward trend line price chart, BABA shares could reach $1,000 sometime in the first quarter of 2027 if it crawls along with the support level.Alibaba's P/E ratio would compress to a mere 11 ti","content":"<p><b>Summary</b></p>\n<ul>\n <li>The \"promotional period\" for BABA shares has gone on for too long and patience is wearing thin. On the other hand, there's a camp of investors who welcome this.</li>\n <li>Alibaba has considerably more challenges on hand now than in early 2019 (U.S.-China trade war), yet the share price manages to be substantially higher.</li>\n <li>Drawing a straightforward trend line price chart, BABA shares could reach $1,000 sometime in the first quarter of 2027 if it crawls along with the support level.</li>\n <li>Alibaba's P/E ratio would compress to a mere 11 times on a forward basis (FY2026) and this is based on the current depressed environment.</li>\n <li>An investment in Alibaba has several risk factors and I wish to highlight two key ones.</li>\n</ul>\n<p><b>BABA stock is on sale</b></p>\n<p>Like the millions of items on its platforms, Alibaba Group (BABA) is on sale. Unfortunately, for many shareholders, the \"promotional period\" has gone on for too long and patience is wearing thin. On the other hand, there's a camp of investors who welcome this as it allows them to continue adding to their shares.</p>\n<p>Regardless, as a writer on numerousChinese internet stockswhose share prices have remained depressed for months and reading the harsh comments, it can get disheartening. As a shareholder in several of them myself, I understand the emotions going through the mind.</p>\n<p>At the same time, there have been many wise readers and fellow authors who provided sound advice that keeps me on the path. For instance, Gary Alexander recently wrote regarding thetech sell-off:</p>\n<blockquote>\n \"When the selloff in the tech sector has proven to be this indiscriminate (good and bad, cheap and expensive stocks are all being sold off at roughly the same pace), it's our job as diligent investors to be extremely discerning in the buying opportunities that have surfaced.\"\n</blockquote>\n<p>With BABA stock having given up all its gains in the past year, it's scant comfort to know the share price is still 58 percent higher than early 2019. Nevertheless, I am bringing this up because Alibaba was being shunned by investors then due to the headwinds from the U.S.-China trade war.</p>\n<p><img src=\"https://static.tigerbbs.com/e90c1a30b5b83eb51c67338eab37cb5e\" tg-width=\"640\" tg-height=\"451\" referrerpolicy=\"no-referrer\"></p>\n<p>Now that the e-commerce and cloud giant has considerably more challenges on hand, yet the share price manages to be substantially higher. This provides a glimpse into the possible future where Alibaba Group Holding Limited overcome its immediate struggles and investors clamor for its shares again.</p>\n<p>That said, how do we justify that BABA stock is on sale? Well, let's look at the valuation. Both Alibaba Group and its U.S. peer Amazon.com (AMZN) have delivered solid revenue and earnings growth in the past years. The improvement in business fundamentals has led investors in both companies to think it would only get tougher to achieve returns expected of a growth stock, compressing their price-earnings multiples.</p>\n<p>Looking at the more representative enterprise value to free cash flow [EV/FCF] ratio, it becomes apparent that the market is valuing Alibaba much lower than Amazon. The EV/FCF is only 16 times for Alibaba and 72 times for Amazon.</p>\n<p><img src=\"https://static.tigerbbs.com/57bda237a374d7f6688c298b0fe9ae21\" tg-width=\"640\" tg-height=\"493\" referrerpolicy=\"no-referrer\"></p>\n<p>With a 3-year revenue CAGR and a 5-year revenue CAGR above 40 percent, it's hard to argue Alibaba Group is not a growth stock. Amazon only managed to deliver around 30 percent CAGR for both its 3-year and 5-year revenues. For the last reported quarter, Alibaba scored a 64 percent increase in revenue. Its forward revenue growth of 35.3 percent surpasses that of Amazon as well.</p>\n<table>\n <tbody>\n  <tr>\n   <td>BABA</td>\n   <td>AMZN</td>\n  </tr>\n  <tr>\n   <td>Revenue Growth [YoY]</td>\n   <td><p>40.7%</p></td>\n   <td><p>41.5%</p></td>\n  </tr>\n  <tr>\n   <td>Revenue Growth [FWD]</td>\n   <td><p>35.3%</p></td>\n   <td><p>27.2%</p></td>\n  </tr>\n  <tr>\n   <td>Revenue 3 Year [CAGR]</td>\n   <td><p>42.1%</p></td>\n   <td><p>29.5%</p></td>\n  </tr>\n  <tr>\n   <td>Revenue 5 Year [CAGR]</td>\n   <td><p>48.0%</p></td>\n   <td><p>29.9%</p></td>\n  </tr>\n </tbody>\n</table>\n<p><i>Source: Seeking Alpha Premium (data extracted on June 6, 2021)</i></p>\n<p>During times of uncertainty, it is imperative that companies have plenty of liquidity. Alibaba has loads of cash. Its EV to net cash is at a low 11.5 times compared to 36.6 times for Amazon. In other words, Alibaba has much more cash at its disposal relative to Amazon when we compare the enterprise values of the two companies. With the financial heft to withstand regulatory changes and geopolitical headwinds, it seems BABA shares are now at a bargain.</p>\n<p><b>Alibaba stock forecast</b></p>\n<p>The circumstances leading to the rough patch that Alibaba Group has found itself in are well-publicized. For the uninitiated, here are the key hurdles the company has faced:</p>\n<ul>\n <li>Theeleventh-hour suspensionof the IPO of Ant Group, its fintech arm;</li>\n <li>The\"disappearance\" of Jack Ma, the flamboyant founder of Alibaba Group;</li>\n <li>Antimonopoly investigation on its e-commerce practices and the subsequentpenalty meted out;</li>\n <li>Restructuring of Ant Group such that its finance lending unit isregulated like a bank, crimping its valuation.</li>\n</ul>\n<p>Considering the earlier mentioned formidable headwinds, it might seem ludicrous to think BABA stock can hit $1000 per share, more than quadruple the current price. Nevertheless, drawing a straightforward trend line price chart, BABA shares could reach $1000 sometime in the first quarter of 2027, if it crawls along with the support level.</p>\n<p><img src=\"https://static.tigerbbs.com/00dc7dd1ce5e1c05708abe460be89359\" tg-width=\"640\" tg-height=\"249\" referrerpolicy=\"no-referrer\"></p>\n<p><i>Source: Yahoo Finance (chart drawn by ALT Perspective)</i></p>\n<p>Do note that I am not factoring in any share consolidation in the interim. I am also not considering the scenario that Alibaba becomes a meme stock which is possible since Redditors tend to promote stocks that are \"hated\" by the market. I am assuming the adage that the stock market is a weighing machine, in the long run, will come to fruition for BABA.</p>\n<p>Is that thought farfetched? Just a couple of months back, I would answer a categorical no. However, as you will see from the chart, BABA's share price has dipped below the long-term support line. Some stocks have experienced such a chart pattern and managed to return above the support-turned-resistance line. It would not be easy but it has happened.</p>\n<p>Of course, the question here is whether $1000 per share is something foreseeable in the future. I say yes, provided the stock can regain its composure and get back up to the multi-year trend line in the next few months or so. If the stock drifts further south instead, the recovery back to the long-term support line would be too onerous, not to mention to get back on the track to $1000.</p>\n<p>The consensus one-year price target for BABA is at $295.60, 37 percent above the prevailing price. Even if the price target does not get revised upwards through the rest of the year, hitting near that level would bring the share price well above the $278 where the support line will be at the end of 2021. This means it isn't that difficult for Alibaba to return to its uptrend.</p>\n<p><img src=\"https://static.tigerbbs.com/6a8487c8f5276e6dd30d79d024833563\" tg-width=\"640\" tg-height=\"478\" referrerpolicy=\"no-referrer\"></p>\n<p><b>Is Alibaba a good long-term stock?</b></p>\n<p>It is common nowadays to read media headlines and comments about fund managers \"dumping BABA stock\". Thus, it came as a surprise to me that Alibaba Group Holding was ranked fifth among \"50 stocks that matter the most to hedge funds,\" according to the Goldman Sachs'Hedge Fund VIP List.</p>\n<p>As many as 77 funds with 10 to 200 positions have Alibaba Group in their portfolios as of 31 March 2021, way higher than the median of 44 for the other stocks. Alibaba even found itself in the top 10 holdings in 35 funds. The average portfolio weight of BABA stock in these funds was 6 percent, the same weighting as Amazon and Visa Inc. (V). The percentage of equity cap of Alibaba owned by hedge funds was 2 percent, also the same as Amazon.</p>\n<p>Masayoshi Son, the CEO of SoftBank Group (OTCPK:SFTBY) (OTCPK:SFTBF), recently commented that Alibaba is \"a great company, at a low price compared with its fundamentals.\" As SoftBank is a substantial shareholder of Alibaba, perhaps some readers are not convinced.</p>\n<p>However, Alibaba is becoming such a value stock that even \"Warren Buffett would love,\" according to a recent<i>Barron's</i>article. In a selection of high-scoring U.S. stocks from the Validea Buffett model, with market values above $10 billion, Alibaba Group was among the 10 finalists. Of particular note, it received a perfect score based on the Buffett model.</p>\n<p>What are we missing here? According to the consensus forecast, Alibaba is projected to double its earnings per share to nearly $20 in fiscal year ending March 2026, up from the $10.10 it reported in the fiscal year ending March 2021. Correspondingly, its P/E ratio would compress to a mere 11 times on a forward basis, if the share price stayed stagnant.</p>\n<p><img src=\"https://static.tigerbbs.com/3e98d8e98b1ce9bd2ec6a1275eb329f9\" tg-width=\"640\" tg-height=\"276\" referrerpolicy=\"no-referrer\"></p>\n<p><i>Source: Seeking Alpha Premium</i></p>\n<p>If the share price does reach $1000, the P/E ratio would be more than 40 times. That would mean a rather rich valuation for Alibaba. However, we have to consider that the formidable headwinds facing the company have resulted in analysts churning out conservative numbers and price targets. As we can see from the following table, the EPS forecast is premised on the revenue growth steadily declining from the 5-year revenue CAGR of 48 percent to the low teens by 2026.</p>\n<p><img src=\"https://static.tigerbbs.com/7b2476ae016bd40d9b86476464121313\" tg-width=\"640\" tg-height=\"207\" referrerpolicy=\"no-referrer\"></p>\n<p><i>Source: Seeking Alpha Premium</i></p>\n<p>When Alibaba Group continues to deliver steady revenue and earnings growth over the coming years, coupled with a potentialsustained change in narrative, the sentiment towards the stock could switch back to positive and we could once again see analysts revising their projections in reaction.</p>\n<p><b>Risk factors for Alibaba investors</b></p>\n<p>An investment in Alibaba has several risk factors and I wish to highlight two key ones. First, its ADR shares are listed through a Variable Interest Entity [VIE] structure. Some analysts haveraised the concernthat the Chinese government could one day declare the VIE void and the shares could become worthless overnight technically.</p>\n<p>Rationally though, it does not make sense for Beijing to disavow the VIE structure. Listing on the U.S. markets enables its companies to secure funding for business growth which would, in turn, boost the Chinese economy as well as create jobs.</p>\n<p>Second, the Holding Foreign Companies Accountable Act [HFCAA]signed into lawon 18 December 2020 could result in BABA ADRs delisted from U.S. stock exchanges if Alibaba is unable to fulfill the conditions as stipulated in the Act. The company CFO, Maggie Wu, has expressed her confidence that Alibaba cancomply withthe requirements of the HFCAA.</p>\n<p>Nevertheless, the U.S. government can issue amendments to the Act as it hasdone soin March. There is no certainty that Alibaba would be able to meet all future changes to the HFCAA. Investors have to take such risks into consideration.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Can Alibaba Stock Hit $1,000? What's The Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCan Alibaba Stock Hit $1,000? What's The Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-10 17:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4433917-can-alibaba-stock-hit-1000><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nThe \"promotional period\" for BABA shares has gone on for too long and patience is wearing thin. On the other hand, there's a camp of investors who welcome this.\nAlibaba has considerably more ...</p>\n\n<a href=\"https://seekingalpha.com/article/4433917-can-alibaba-stock-hit-1000\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BABA":"阿里巴巴","09988":"阿里巴巴-W"},"source_url":"https://seekingalpha.com/article/4433917-can-alibaba-stock-hit-1000","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1107871315","content_text":"Summary\n\nThe \"promotional period\" for BABA shares has gone on for too long and patience is wearing thin. On the other hand, there's a camp of investors who welcome this.\nAlibaba has considerably more challenges on hand now than in early 2019 (U.S.-China trade war), yet the share price manages to be substantially higher.\nDrawing a straightforward trend line price chart, BABA shares could reach $1,000 sometime in the first quarter of 2027 if it crawls along with the support level.\nAlibaba's P/E ratio would compress to a mere 11 times on a forward basis (FY2026) and this is based on the current depressed environment.\nAn investment in Alibaba has several risk factors and I wish to highlight two key ones.\n\nBABA stock is on sale\nLike the millions of items on its platforms, Alibaba Group (BABA) is on sale. Unfortunately, for many shareholders, the \"promotional period\" has gone on for too long and patience is wearing thin. On the other hand, there's a camp of investors who welcome this as it allows them to continue adding to their shares.\nRegardless, as a writer on numerousChinese internet stockswhose share prices have remained depressed for months and reading the harsh comments, it can get disheartening. As a shareholder in several of them myself, I understand the emotions going through the mind.\nAt the same time, there have been many wise readers and fellow authors who provided sound advice that keeps me on the path. For instance, Gary Alexander recently wrote regarding thetech sell-off:\n\n \"When the selloff in the tech sector has proven to be this indiscriminate (good and bad, cheap and expensive stocks are all being sold off at roughly the same pace), it's our job as diligent investors to be extremely discerning in the buying opportunities that have surfaced.\"\n\nWith BABA stock having given up all its gains in the past year, it's scant comfort to know the share price is still 58 percent higher than early 2019. Nevertheless, I am bringing this up because Alibaba was being shunned by investors then due to the headwinds from the U.S.-China trade war.\n\nNow that the e-commerce and cloud giant has considerably more challenges on hand, yet the share price manages to be substantially higher. This provides a glimpse into the possible future where Alibaba Group Holding Limited overcome its immediate struggles and investors clamor for its shares again.\nThat said, how do we justify that BABA stock is on sale? Well, let's look at the valuation. Both Alibaba Group and its U.S. peer Amazon.com (AMZN) have delivered solid revenue and earnings growth in the past years. The improvement in business fundamentals has led investors in both companies to think it would only get tougher to achieve returns expected of a growth stock, compressing their price-earnings multiples.\nLooking at the more representative enterprise value to free cash flow [EV/FCF] ratio, it becomes apparent that the market is valuing Alibaba much lower than Amazon. The EV/FCF is only 16 times for Alibaba and 72 times for Amazon.\n\nWith a 3-year revenue CAGR and a 5-year revenue CAGR above 40 percent, it's hard to argue Alibaba Group is not a growth stock. Amazon only managed to deliver around 30 percent CAGR for both its 3-year and 5-year revenues. For the last reported quarter, Alibaba scored a 64 percent increase in revenue. Its forward revenue growth of 35.3 percent surpasses that of Amazon as well.\n\n\n\nBABA\nAMZN\n\n\nRevenue Growth [YoY]\n40.7%\n41.5%\n\n\nRevenue Growth [FWD]\n35.3%\n27.2%\n\n\nRevenue 3 Year [CAGR]\n42.1%\n29.5%\n\n\nRevenue 5 Year [CAGR]\n48.0%\n29.9%\n\n\n\nSource: Seeking Alpha Premium (data extracted on June 6, 2021)\nDuring times of uncertainty, it is imperative that companies have plenty of liquidity. Alibaba has loads of cash. Its EV to net cash is at a low 11.5 times compared to 36.6 times for Amazon. In other words, Alibaba has much more cash at its disposal relative to Amazon when we compare the enterprise values of the two companies. With the financial heft to withstand regulatory changes and geopolitical headwinds, it seems BABA shares are now at a bargain.\nAlibaba stock forecast\nThe circumstances leading to the rough patch that Alibaba Group has found itself in are well-publicized. For the uninitiated, here are the key hurdles the company has faced:\n\nTheeleventh-hour suspensionof the IPO of Ant Group, its fintech arm;\nThe\"disappearance\" of Jack Ma, the flamboyant founder of Alibaba Group;\nAntimonopoly investigation on its e-commerce practices and the subsequentpenalty meted out;\nRestructuring of Ant Group such that its finance lending unit isregulated like a bank, crimping its valuation.\n\nConsidering the earlier mentioned formidable headwinds, it might seem ludicrous to think BABA stock can hit $1000 per share, more than quadruple the current price. Nevertheless, drawing a straightforward trend line price chart, BABA shares could reach $1000 sometime in the first quarter of 2027, if it crawls along with the support level.\n\nSource: Yahoo Finance (chart drawn by ALT Perspective)\nDo note that I am not factoring in any share consolidation in the interim. I am also not considering the scenario that Alibaba becomes a meme stock which is possible since Redditors tend to promote stocks that are \"hated\" by the market. I am assuming the adage that the stock market is a weighing machine, in the long run, will come to fruition for BABA.\nIs that thought farfetched? Just a couple of months back, I would answer a categorical no. However, as you will see from the chart, BABA's share price has dipped below the long-term support line. Some stocks have experienced such a chart pattern and managed to return above the support-turned-resistance line. It would not be easy but it has happened.\nOf course, the question here is whether $1000 per share is something foreseeable in the future. I say yes, provided the stock can regain its composure and get back up to the multi-year trend line in the next few months or so. If the stock drifts further south instead, the recovery back to the long-term support line would be too onerous, not to mention to get back on the track to $1000.\nThe consensus one-year price target for BABA is at $295.60, 37 percent above the prevailing price. Even if the price target does not get revised upwards through the rest of the year, hitting near that level would bring the share price well above the $278 where the support line will be at the end of 2021. This means it isn't that difficult for Alibaba to return to its uptrend.\n\nIs Alibaba a good long-term stock?\nIt is common nowadays to read media headlines and comments about fund managers \"dumping BABA stock\". Thus, it came as a surprise to me that Alibaba Group Holding was ranked fifth among \"50 stocks that matter the most to hedge funds,\" according to the Goldman Sachs'Hedge Fund VIP List.\nAs many as 77 funds with 10 to 200 positions have Alibaba Group in their portfolios as of 31 March 2021, way higher than the median of 44 for the other stocks. Alibaba even found itself in the top 10 holdings in 35 funds. The average portfolio weight of BABA stock in these funds was 6 percent, the same weighting as Amazon and Visa Inc. (V). The percentage of equity cap of Alibaba owned by hedge funds was 2 percent, also the same as Amazon.\nMasayoshi Son, the CEO of SoftBank Group (OTCPK:SFTBY) (OTCPK:SFTBF), recently commented that Alibaba is \"a great company, at a low price compared with its fundamentals.\" As SoftBank is a substantial shareholder of Alibaba, perhaps some readers are not convinced.\nHowever, Alibaba is becoming such a value stock that even \"Warren Buffett would love,\" according to a recentBarron'sarticle. In a selection of high-scoring U.S. stocks from the Validea Buffett model, with market values above $10 billion, Alibaba Group was among the 10 finalists. Of particular note, it received a perfect score based on the Buffett model.\nWhat are we missing here? According to the consensus forecast, Alibaba is projected to double its earnings per share to nearly $20 in fiscal year ending March 2026, up from the $10.10 it reported in the fiscal year ending March 2021. Correspondingly, its P/E ratio would compress to a mere 11 times on a forward basis, if the share price stayed stagnant.\n\nSource: Seeking Alpha Premium\nIf the share price does reach $1000, the P/E ratio would be more than 40 times. That would mean a rather rich valuation for Alibaba. However, we have to consider that the formidable headwinds facing the company have resulted in analysts churning out conservative numbers and price targets. As we can see from the following table, the EPS forecast is premised on the revenue growth steadily declining from the 5-year revenue CAGR of 48 percent to the low teens by 2026.\n\nSource: Seeking Alpha Premium\nWhen Alibaba Group continues to deliver steady revenue and earnings growth over the coming years, coupled with a potentialsustained change in narrative, the sentiment towards the stock could switch back to positive and we could once again see analysts revising their projections in reaction.\nRisk factors for Alibaba investors\nAn investment in Alibaba has several risk factors and I wish to highlight two key ones. First, its ADR shares are listed through a Variable Interest Entity [VIE] structure. Some analysts haveraised the concernthat the Chinese government could one day declare the VIE void and the shares could become worthless overnight technically.\nRationally though, it does not make sense for Beijing to disavow the VIE structure. Listing on the U.S. markets enables its companies to secure funding for business growth which would, in turn, boost the Chinese economy as well as create jobs.\nSecond, the Holding Foreign Companies Accountable Act [HFCAA]signed into lawon 18 December 2020 could result in BABA ADRs delisted from U.S. stock exchanges if Alibaba is unable to fulfill the conditions as stipulated in the Act. The company CFO, Maggie Wu, has expressed her confidence that Alibaba cancomply withthe requirements of the HFCAA.\nNevertheless, the U.S. government can issue amendments to the Act as it hasdone soin March. There is no certainty that Alibaba would be able to meet all future changes to the HFCAA. Investors have to take such risks into consideration.","news_type":1},"isVote":1,"tweetType":1,"viewCount":624,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9081520206,"gmtCreate":1650254815805,"gmtModify":1676534680283,"author":{"id":"3564047369816792","authorId":"3564047369816792","name":"ETJF","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564047369816792","authorIdStr":"3564047369816792"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9081520206","repostId":"2228556987","repostType":4,"repost":{"id":"2228556987","pubTimestamp":1650252456,"share":"https://ttm.financial/m/news/2228556987?lang=&edition=fundamental","pubTime":"2022-04-18 11:27","market":"us","language":"en","title":"Pfizer Draws Skeptics Amid Concerns Over Outlook for COVID-Related Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2228556987","media":"seekingalpha","summary":"The earning season of large-cap pharma is set to kick off this week with the first quarter financial","content":"<html><head></head><body><p>The earning season of large-cap pharma is set to kick off this week with the first quarter financials of Johnson &amp; Johnson (JNJ). However, amid a recent selloff and a sharp decline in COVID-19 cases, its rival <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> has gained attention on Wall Street over the prospects for its COVID-related sales.</p><p>Despite a sharp recovery last month, <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> continues to trade 10% lower than its level at the start of the year, while J&amp;J (JNJ) and Merck (MRK), two of its pharma rivals with COVID-reliant businesses, have added ~5% and ~12%, respectively.</p><p>“For Pfizer, forecasting Comirnaty and Paxlovid remains a challenge,” Mizuho analysts led by Vamil Divan wrote this week, referring to the company’s COVID-19 vaccine and the antiviral by their brand names. With its 4Q 2021 results in February, the New York-based pharma giant projected $98B – $102B in revenue for this year, with more than half of the estimate attributed to the vaccine and pill sales at the midpoint of the forecast, based on contracts signed as of late-January.</p><p>Citing <a href=\"https://laohu8.com/S/IQV\">IQVIA</a> prescription trends, Mizuho expects the company to report 1Q 2022 revenue in line with the consensus. However, the analysts project lower than expected sales for Paxlovid, the breast cancer therapy, Ibrance and JAK inhibitor, Xeljanz.</p><p>Meanwhile, the sales of the COVID-19 vaccine could exceed Street forecasts driven by the demand outside the U.S., the team wrote, adding that sales of Pfizer&#39;s (PFE) heart failure therapy, Vyndamax, could also surpass expectations.</p><p>However, citing lower estimates for Comirnaty and Paxlovid, the firm has cut the 1Q revenue and EPS estimates for the company by ~12% and ~9% to $24.79B and $1.57, respectively.</p><p>Despite the success with the vaccine and pill, Mizuho reiterates the Neutral rating and $55 per share target on Pfizer (PFE) as the analysts point to the need for “more signs of pipeline success that will have a greater impact on Pfizer’s 2026-2030 outlook.”</p><p>The murky prospects for Pfizer’s (PFE) COVID-19 vaccine, its leading revenue generator last year, seem to have weighed on its valuation. Just last week, data analytics firm Airfinity cut the 2022 sales forecast for the vaccine by 15%.</p><p>However, after a two-month decline, the COVID-19 cases are on the rise in the U.S. again, fueled by highly transmissible Omicron BA. 2 subvariant. The data from Johns Hopkins University indicate that the daily new cases have climbed 14% since the start of April to approximately 32,000 cases per day, <i>The Financial Times</i> reported Saturday.</p><p>A potential uptick in COVID cases could make Pfizer&#39;s (PFE) valuation even more attractive, particularly after the recent selloff. On a non-GAAP basis, Pfizer’s (PFE) forward P/E stands at ~7.4x, with a ~42% discount to the five-year average, while those of rivals Merck (MRK) and J&amp;J (JNJ), which attributed ~10% and ~3% of 2022 revenue forecast to COVID-related sales, hover around ~12.0x and ~17.1x, respectively.</p><p>To become more constructive on Pfizer&#39;s (PFE) thesis, Divan and the Mizuho team seek further clarity on how the company will deploy the cashflows it generated from the vaccine and pill to improve its long-term outlook.</p><p>At a time the biotech valuations look compelling, the company appears to be on the deal hunt. Last month, it completed the acquisition of Arena Pharmaceuticals, a clinical-stage biotech focused on immuno-inflammatory diseases.</p><p>Announcing a proposed $525M deal to acquire privately-held ReViral, Pfizer (PFE) said early this month that the clinical-stage biopharma company could add over $1.5B in annual revenue if its programs become successful.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Draws Skeptics Amid Concerns Over Outlook for COVID-Related Sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Draws Skeptics Amid Concerns Over Outlook for COVID-Related Sales\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-18 11:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3823672-pfe-stock-in-focus-amid-concerns-over-outlook-for-covid-related-sales><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The earning season of large-cap pharma is set to kick off this week with the first quarter financials of Johnson & Johnson (JNJ). However, amid a recent selloff and a sharp decline in COVID-19 cases, ...</p>\n\n<a href=\"https://seekingalpha.com/news/3823672-pfe-stock-in-focus-amid-concerns-over-outlook-for-covid-related-sales\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://seekingalpha.com/news/3823672-pfe-stock-in-focus-amid-concerns-over-outlook-for-covid-related-sales","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2228556987","content_text":"The earning season of large-cap pharma is set to kick off this week with the first quarter financials of Johnson & Johnson (JNJ). However, amid a recent selloff and a sharp decline in COVID-19 cases, its rival Pfizer has gained attention on Wall Street over the prospects for its COVID-related sales.Despite a sharp recovery last month, Pfizer continues to trade 10% lower than its level at the start of the year, while J&J (JNJ) and Merck (MRK), two of its pharma rivals with COVID-reliant businesses, have added ~5% and ~12%, respectively.“For Pfizer, forecasting Comirnaty and Paxlovid remains a challenge,” Mizuho analysts led by Vamil Divan wrote this week, referring to the company’s COVID-19 vaccine and the antiviral by their brand names. With its 4Q 2021 results in February, the New York-based pharma giant projected $98B – $102B in revenue for this year, with more than half of the estimate attributed to the vaccine and pill sales at the midpoint of the forecast, based on contracts signed as of late-January.Citing IQVIA prescription trends, Mizuho expects the company to report 1Q 2022 revenue in line with the consensus. However, the analysts project lower than expected sales for Paxlovid, the breast cancer therapy, Ibrance and JAK inhibitor, Xeljanz.Meanwhile, the sales of the COVID-19 vaccine could exceed Street forecasts driven by the demand outside the U.S., the team wrote, adding that sales of Pfizer's (PFE) heart failure therapy, Vyndamax, could also surpass expectations.However, citing lower estimates for Comirnaty and Paxlovid, the firm has cut the 1Q revenue and EPS estimates for the company by ~12% and ~9% to $24.79B and $1.57, respectively.Despite the success with the vaccine and pill, Mizuho reiterates the Neutral rating and $55 per share target on Pfizer (PFE) as the analysts point to the need for “more signs of pipeline success that will have a greater impact on Pfizer’s 2026-2030 outlook.”The murky prospects for Pfizer’s (PFE) COVID-19 vaccine, its leading revenue generator last year, seem to have weighed on its valuation. Just last week, data analytics firm Airfinity cut the 2022 sales forecast for the vaccine by 15%.However, after a two-month decline, the COVID-19 cases are on the rise in the U.S. again, fueled by highly transmissible Omicron BA. 2 subvariant. The data from Johns Hopkins University indicate that the daily new cases have climbed 14% since the start of April to approximately 32,000 cases per day, The Financial Times reported Saturday.A potential uptick in COVID cases could make Pfizer's (PFE) valuation even more attractive, particularly after the recent selloff. On a non-GAAP basis, Pfizer’s (PFE) forward P/E stands at ~7.4x, with a ~42% discount to the five-year average, while those of rivals Merck (MRK) and J&J (JNJ), which attributed ~10% and ~3% of 2022 revenue forecast to COVID-related sales, hover around ~12.0x and ~17.1x, respectively.To become more constructive on Pfizer's (PFE) thesis, Divan and the Mizuho team seek further clarity on how the company will deploy the cashflows it generated from the vaccine and pill to improve its long-term outlook.At a time the biotech valuations look compelling, the company appears to be on the deal hunt. Last month, it completed the acquisition of Arena Pharmaceuticals, a clinical-stage biotech focused on immuno-inflammatory diseases.Announcing a proposed $525M deal to acquire privately-held ReViral, Pfizer (PFE) said early this month that the clinical-stage biopharma company could add over $1.5B in annual revenue if its programs become successful.","news_type":1},"isVote":1,"tweetType":1,"viewCount":110,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":182121550,"gmtCreate":1623558716970,"gmtModify":1704206161473,"author":{"id":"3564047369816792","authorId":"3564047369816792","name":"ETJF","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564047369816792","authorIdStr":"3564047369816792"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/182121550","repostId":"1185020128","repostType":4,"repost":{"id":"1185020128","pubTimestamp":1623537503,"share":"https://ttm.financial/m/news/1185020128?lang=&edition=fundamental","pubTime":"2021-06-13 06:38","market":"us","language":"en","title":"Meme Stock Soars 1,000% To Lead These Two Top Small Cap Stock Plays","url":"https://stock-news.laohu8.com/highlight/detail?id=1185020128","media":"investors","summary":"GameStop may be the top holding in SPDR S&P 600 Small Cap Value, but that's not the only reason the ","content":"<p>GameStop may be the top holding in SPDR S&amp;P 600 Small Cap Value, but that's not the only reason the ETF is beating its growth-stock counterpart.</p>\n<p>The $4.2 billion value fund tracks the S&amp;P SmallCap 600 Value Index (SLYV), composed of stocks with the strongest value traits based on book value to price ratio, earnings to price ratio, and sales to price ratio. SLYV rallied 32% this year through Thursday's close.</p>\n<p>That more than doubles the return of its growth stock counterpart, SPDR S&amp;P 600 Small Cap Growth (SLYG), which is up 15%. The index SLYG tracks includes stocks with the strongest growth traits based on sales growth, earnings change to price and momentum.</p>\n<p>Back to SLYV, financials accounted for the biggest sector weight at 24% of assets. Industrials weighed in at about 17%, consumer discretionary 15% and real estate 10%. Information technology was next at 8% and materials, energy and health care, 6% each.&nbsp;Smaller positions in consumer staples, utilities and communication services made up the rest.</p>\n<p>SPDR S&amp;P 600 Small Cap Value is in IBD's ETF Leaders, but SPDR S&amp;P 600 Small Cap Growth is not.</p>\n<p><b>GameStop Stock Leads</b></p>\n<p><b>GameStop</b>(GME),<b>Macy's</b>(M),<b>PDC Energy</b>(PDCE),<b>Resideo Technologies</b>(REZI) and<b>BankUnited</b>(BKU) were the top five holdings as of Wednesday.</p>\n<p><b>Pacific Premier Bancorp</b>(PPBI),<b>Bed Bath &amp; Beyond</b>(BBBY),<b>Ameris Bancorp</b>(ABCB),<b>First Hawaiian</b>(FHB) and<b>Insight Enterprises</b>(NSIT) rounded out the top 10.</p>\n<p>GameStop has undergone wide swings this year. It rocketed about 2,500% early this year amid theshort-squeeze rallyfueled by the Reddit/WallStreetBets crowd.GME stockthen crashed 92% from a Jan. 28 high to its mid-February low. That was followed by an 805% surge the next three weeks, and a 66% drop over the next two weeks.</p>\n<p>Action had been relatively subdued since, until Thursday's 27% dive. Even after that, GameStop stock was up 1,070% year to date through Thursday's close.</p>\n<p>Could GME be inflating SLYV's performance? Certainly, given its quadruple-digit gain. But a look at SLYG's portfolio is interesting. GameStop stock is also the top holding in the growth stock ETF, though the rest of the top 10 differ vastly.</p>\n<p><b>Second Meme Stock In Top 10</b></p>\n<p>PDC Energy, up 130%, saw the next biggest gain in the top 10. The Colorado-based oil and gas explorer has a 97Relative Strength Rating, which mean it's in the top 3% of all stocks. Its relative strength line is at a 52-week high, a bullish sign.</p>\n<p>Bed Bath &amp; Beyond, another meme stock, is up 78% this year. Shares surged more than 200% in January, amid a spate of wild double-digit swings. BBBY stock then gave back the bulk of its gains.</p>\n<p>But the home goods retailer appears to be back on the radar of the WallStreetBets discussion group. On June 2, Bed Bath &amp; Beyond soared 62% before diving 28% the next session.</p>\n<p>The rest of the top 10 stocks have also outperformed the broader market. Macy's is up 68% year to date, while Resideo, Pacific Premier and Ameris have risen more than 40% each. The lowest gainer, bank holding company First Hawaiian, has advanced 20%. The S&amp;P 500 held a 13% gain through Thursday's close.</p>\n<p>SLYV remains in potential buy range from an 87.29entryof acup with handle, according toMarketSmithchart analysis.&nbsp;SLYV and SLYG charge a 0.15% expense ratio.</p>","source":"lsy1610449120050","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Meme Stock Soars 1,000% To Lead These Two Top Small Cap Stock Plays</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMeme Stock Soars 1,000% To Lead These Two Top Small Cap Stock Plays\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-13 06:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.investors.com/etfs-and-funds/etf-leaders/gamestop-stock-soars-1000-percent-lead-two-top-small-cap-stock-plays/?src=A00220><strong>investors</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>GameStop may be the top holding in SPDR S&P 600 Small Cap Value, but that's not the only reason the ETF is beating its growth-stock counterpart.\nThe $4.2 billion value fund tracks the S&P SmallCap 600...</p>\n\n<a href=\"https://www.investors.com/etfs-and-funds/etf-leaders/gamestop-stock-soars-1000-percent-lead-two-top-small-cap-stock-plays/?src=A00220\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BBBY":"3B家居","PDCE":"PDC Energy"},"source_url":"https://www.investors.com/etfs-and-funds/etf-leaders/gamestop-stock-soars-1000-percent-lead-two-top-small-cap-stock-plays/?src=A00220","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1185020128","content_text":"GameStop may be the top holding in SPDR S&P 600 Small Cap Value, but that's not the only reason the ETF is beating its growth-stock counterpart.\nThe $4.2 billion value fund tracks the S&P SmallCap 600 Value Index (SLYV), composed of stocks with the strongest value traits based on book value to price ratio, earnings to price ratio, and sales to price ratio. SLYV rallied 32% this year through Thursday's close.\nThat more than doubles the return of its growth stock counterpart, SPDR S&P 600 Small Cap Growth (SLYG), which is up 15%. The index SLYG tracks includes stocks with the strongest growth traits based on sales growth, earnings change to price and momentum.\nBack to SLYV, financials accounted for the biggest sector weight at 24% of assets. Industrials weighed in at about 17%, consumer discretionary 15% and real estate 10%. Information technology was next at 8% and materials, energy and health care, 6% each. Smaller positions in consumer staples, utilities and communication services made up the rest.\nSPDR S&P 600 Small Cap Value is in IBD's ETF Leaders, but SPDR S&P 600 Small Cap Growth is not.\nGameStop Stock Leads\nGameStop(GME),Macy's(M),PDC Energy(PDCE),Resideo Technologies(REZI) andBankUnited(BKU) were the top five holdings as of Wednesday.\nPacific Premier Bancorp(PPBI),Bed Bath & Beyond(BBBY),Ameris Bancorp(ABCB),First Hawaiian(FHB) andInsight Enterprises(NSIT) rounded out the top 10.\nGameStop has undergone wide swings this year. It rocketed about 2,500% early this year amid theshort-squeeze rallyfueled by the Reddit/WallStreetBets crowd.GME stockthen crashed 92% from a Jan. 28 high to its mid-February low. That was followed by an 805% surge the next three weeks, and a 66% drop over the next two weeks.\nAction had been relatively subdued since, until Thursday's 27% dive. Even after that, GameStop stock was up 1,070% year to date through Thursday's close.\nCould GME be inflating SLYV's performance? Certainly, given its quadruple-digit gain. But a look at SLYG's portfolio is interesting. GameStop stock is also the top holding in the growth stock ETF, though the rest of the top 10 differ vastly.\nSecond Meme Stock In Top 10\nPDC Energy, up 130%, saw the next biggest gain in the top 10. The Colorado-based oil and gas explorer has a 97Relative Strength Rating, which mean it's in the top 3% of all stocks. Its relative strength line is at a 52-week high, a bullish sign.\nBed Bath & Beyond, another meme stock, is up 78% this year. Shares surged more than 200% in January, amid a spate of wild double-digit swings. BBBY stock then gave back the bulk of its gains.\nBut the home goods retailer appears to be back on the radar of the WallStreetBets discussion group. On June 2, Bed Bath & Beyond soared 62% before diving 28% the next session.\nThe rest of the top 10 stocks have also outperformed the broader market. Macy's is up 68% year to date, while Resideo, Pacific Premier and Ameris have risen more than 40% each. The lowest gainer, bank holding company First Hawaiian, has advanced 20%. The S&P 500 held a 13% gain through Thursday's close.\nSLYV remains in potential buy range from an 87.29entryof acup with handle, according toMarketSmithchart analysis. SLYV and SLYG charge a 0.15% expense ratio.","news_type":1},"isVote":1,"tweetType":1,"viewCount":607,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":317333114,"gmtCreate":1612415311838,"gmtModify":1704870845655,"author":{"id":"3564047369816792","authorId":"3564047369816792","name":"ETJF","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3564047369816792","authorIdStr":"3564047369816792"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/317333114","repostId":"2108791116","repostType":4,"repost":{"id":"2108791116","pubTimestamp":1612407835,"share":"https://ttm.financial/m/news/2108791116?lang=&edition=fundamental","pubTime":"2021-02-04 11:03","market":"us","language":"en","title":"Ant and Chinese Banks Are Reining In Joint Loans to Consumers","url":"https://stock-news.laohu8.com/highlight/detail?id=2108791116","media":"Bloomberg","summary":"(Bloomberg) -- Ant Group Co. and at least a dozen banks are paring back their years-long cooperation","content":"<p>(Bloomberg) -- Ant Group Co. and at least a dozen banks are paring back their years-long cooperation on consumer lending platforms that fuel the spending of at least 500 million people across China.</p>\n<p>Regulators have signaled their intention to curb online loans in recent months, prompting banks and Ant itself to discuss lending caps, people familiar with the matter said, asking not to be identified discussing a private information.</p>\n<p>Banks in Zhejiang province have been instructed to cut their exposure to Ant via joint loans on the firm’s Jiebei and Huabei platforms, the people said. Some lenders in Shanghai have set a timetable for a gradual reduction in joint offerings, while at least <a href=\"https://laohu8.com/S/AONE\">one</a> in Shandong has completely suspended ties with the firm, the people said.</p>\n<p>The moves have taken place in parallel with Ant’s discussions with Chinese authorities on a restructuring plan. Bloomberg reported on Wednesday that Ant has agreed to become a financial holding company, making it subject to capital requirements similar to those for banks.</p>\n<p>Consumer credit has been crucial in driving growth at Ant’s digital finance business, which contributed 63% of the firm’s revenue in the first half of 2020 before the authorities unleashed a barrage of rules to curb the country’s booming financial technology industry. Regulators also want to prevent any <a href=\"https://laohu8.com/S/AONE.U\">one</a> firm from becoming too dominant.</p>\n<p>The regulators upended a $35 billion initial public offering by Ant Group in November, stunning investors from Shanghai to New York. In a conference call with investors on Tuesday, Alibaba Group Holding Ltd. Chief Executive Officer Daniel Zhang said there is “substantial uncertainty” with Ant’s business and it is difficult to assess the impact of the new regulations. Alibaba owns a third of Ant and both were founded by billionaire Jack Ma.</p>\n<p>Ant declined to comment. The China Banking and Insurance Regulatory Commission didn’t immediately respond to a request seeking comment.</p>\n<p>Among the hardest-hitting for Ant was the proposal to impose additional capital requirements on microlenders and demand that fintech platforms put up at least 30% of the funding for loans that are jointly offered with banks. Before the proposal, only about 2% of the more than 1.7 trillion yuan ($263 billion) in loans remained on Ant’s balance sheet, with the bulk of funding coming from its about 100 bank partners.</p>\n<p>Ant needs to inject at least 70 billion yuan of new capital just for its credit-lending business to comply with the regulation, according to a November estimate by Francis Chan, a senior analyst at Bloomberg Intelligence in Hong Kong.</p>\n<p>Liang Tao, vice chairman of the China Banking and Insurance Regulatory Commission, said last month recent measures weren’t aimed at any specific company and have been well received by some in the industry. Some of the firms have a “relatively positive attitude” toward the new requirements and have achieved “initial effects” in their “rectification” efforts, he said.</p>\n<p>Banks and insurers should continue to cooperate normally with internet platforms in compliance with laws and regulations and some lenders that have pulled back should correct their behavior, Liang said, without elaborating.</p>\n<p>Still, local banking regulators in provinces including Zhejiang and Hunan are urging banks that have relied heavily on Ant for client referrals and lending growth to cut back, said the people.</p>\n<p>“While the restructuring would bring Ant a step closer to relaunching its IPO, all its units face more restrictions on capital, leverage and product pricing, risking growth,” said Chan, who estimated Ant’s valuation may have fallen to below $108 billion from a $280 billion pre-money valuation ahead of its failed IPO.</p>\n<p></p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ant and Chinese Banks Are Reining In Joint Loans to Consumers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnt and Chinese Banks Are Reining In Joint Loans to Consumers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-02-04 11:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/ant-chinese-banks-reining-joint-010651856.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Ant Group Co. and at least a dozen banks are paring back their years-long cooperation on consumer lending platforms that fuel the spending of at least 500 million people across China.\n...</p>\n\n<a href=\"https://finance.yahoo.com/news/ant-chinese-banks-reining-joint-010651856.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/1684aaaa06891b8d2dd04a9941acb502","relate_stocks":{"BABA":"阿里巴巴","09988":"阿里巴巴-W"},"source_url":"https://finance.yahoo.com/news/ant-chinese-banks-reining-joint-010651856.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2108791116","content_text":"(Bloomberg) -- Ant Group Co. and at least a dozen banks are paring back their years-long cooperation on consumer lending platforms that fuel the spending of at least 500 million people across China.\nRegulators have signaled their intention to curb online loans in recent months, prompting banks and Ant itself to discuss lending caps, people familiar with the matter said, asking not to be identified discussing a private information.\nBanks in Zhejiang province have been instructed to cut their exposure to Ant via joint loans on the firm’s Jiebei and Huabei platforms, the people said. Some lenders in Shanghai have set a timetable for a gradual reduction in joint offerings, while at least one in Shandong has completely suspended ties with the firm, the people said.\nThe moves have taken place in parallel with Ant’s discussions with Chinese authorities on a restructuring plan. Bloomberg reported on Wednesday that Ant has agreed to become a financial holding company, making it subject to capital requirements similar to those for banks.\nConsumer credit has been crucial in driving growth at Ant’s digital finance business, which contributed 63% of the firm’s revenue in the first half of 2020 before the authorities unleashed a barrage of rules to curb the country’s booming financial technology industry. Regulators also want to prevent any one firm from becoming too dominant.\nThe regulators upended a $35 billion initial public offering by Ant Group in November, stunning investors from Shanghai to New York. In a conference call with investors on Tuesday, Alibaba Group Holding Ltd. Chief Executive Officer Daniel Zhang said there is “substantial uncertainty” with Ant’s business and it is difficult to assess the impact of the new regulations. Alibaba owns a third of Ant and both were founded by billionaire Jack Ma.\nAnt declined to comment. The China Banking and Insurance Regulatory Commission didn’t immediately respond to a request seeking comment.\nAmong the hardest-hitting for Ant was the proposal to impose additional capital requirements on microlenders and demand that fintech platforms put up at least 30% of the funding for loans that are jointly offered with banks. Before the proposal, only about 2% of the more than 1.7 trillion yuan ($263 billion) in loans remained on Ant’s balance sheet, with the bulk of funding coming from its about 100 bank partners.\nAnt needs to inject at least 70 billion yuan of new capital just for its credit-lending business to comply with the regulation, according to a November estimate by Francis Chan, a senior analyst at Bloomberg Intelligence in Hong Kong.\nLiang Tao, vice chairman of the China Banking and Insurance Regulatory Commission, said last month recent measures weren’t aimed at any specific company and have been well received by some in the industry. Some of the firms have a “relatively positive attitude” toward the new requirements and have achieved “initial effects” in their “rectification” efforts, he said.\nBanks and insurers should continue to cooperate normally with internet platforms in compliance with laws and regulations and some lenders that have pulled back should correct their behavior, Liang said, without elaborating.\nStill, local banking regulators in provinces including Zhejiang and Hunan are urging banks that have relied heavily on Ant for client referrals and lending growth to cut back, said the people.\n“While the restructuring would bring Ant a step closer to relaunching its IPO, all its units face more restrictions on capital, leverage and product pricing, risking growth,” said Chan, who estimated Ant’s valuation may have fallen to below $108 billion from a $280 billion pre-money valuation ahead of its failed IPO.","news_type":1},"isVote":1,"tweetType":1,"viewCount":520,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}